Loading...
 
Back to the list
Mediterr J Rheumatol 2016;27(2):34-5
Article Links
How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience
Piet L.C.M. van Riel
Authors Information
Department of Rheumatology Bernhoven, The Netherlands and Radboud University Medical Center, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, The Netherlands
Keywords: Rheumatoid Arthritis, DMARDs, csDMARDs, bDMARDs, biosimilars, tapering, biological treatment, remission
References
  1. Kievit W, Fransen J, Adang E M, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50:196-203.
  2. Goekoop-Ruiterman Y P M, De Vries-Bouwstra J K, Allaart C F, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
  3. Landewé R B M, Boers M, Verhoeven A C, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
  4. Bakker M F, Jacobs J W G, Welsing P M J, et al. Clinical and epidemiological research: Concise report: Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011;70:1099-103.
  5. Vermeer M, Kuper H H, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63(10):2865-72.
  6. de Jong P H, Hazes J M, Han H K, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73:1331-9.
  7. Ten Wolde S, Breedveld F C, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
  8. Moghadam M G, Vonkeman H E, ten Klooster P M, et al. Stopping Tumor Necrosis Factor-inhibitors in Patients with Established Rheumatoid Arthritis in Remission or Stable Low Disease Activity: A Pragmatic Randomized Multicenter Open-Label Controlled Trial. Arthritis Rheum 2016;68(8):1810-7.
  9. van Herwaarden N, van der Maas A, Minten M J M, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial BMJ 2015;350:h1389.